Address correspondence to: Alfred O. Berg, M.D., M.P.H., Chair, U.S. Preventive Services Task Force, c/o Robert Graham, M.D., Director, Center for Practice and Technology Assessment, Agency for Healthcare Research and Quality, 6010 Executive Boulevard, Suite 300, Rockville, MD 20852.
This statement summarizes the third USPSTF recommendations
for screening for chlamydial infection and the supporting scientific evidence,
and it updates the 1995 recommendations contained in the Guide to Clinical
Preventive Services, second edition (1). Explanations
of the ratings and of the strength of overall evidence are given in Appendix A and Appendix B, respectively. The complete
information upon which this statement is based, including evidence tables
and references, is available in the accompanying article, Screening for Chlamydial
Infection (2) and in the Systematic Evidence Review (3) on this topic.
This article originally appeared in the American Journal of Preventive
Medicine. Select for copyright, source, and reprint information.
Link to the National Guideline Clearinghouse
Recommendation and Rationale Statements present the current U.S. Preventive
Services Task Force (USPSTF) recommendations, the rationale for the recommendation,
and the supporting scientific evidence. These statements address preventive
health services for use in primary care clinical settings, including screening
tests, counseling, and chemoprevention.
The USPSTF recommendations are independent of the U.S. government. They
do not represent the views of the Agency for Healthcare Research and Quality
(AHRQ), the U.S. Department of Health and Human Services, or the U.S. Public
Health Service.
